Daniel founded Shift Bioscience in 2017 during postdoctoral research at The Francis Crick Institute.

Since then, Daniel has led the Company through a sustained period of growth and discovery milestones, operating at the intersection of computational and cellular biology whilst shaping the Company’s vision to develop the first drug pipeline for cellular age reversal in humans.

Daniel holds a Ph.D from the University of Cambridge, where his work focused on harnessing computational biology to discover a novel therapeutic approach for a rare mitochondrial disease. From there his scientific discovery has taken him from the adoption of mouse aging clocks to validate therapeutic hypotheses, to single-cell aging clocks for systematic discovery of aging and rejuvenation biology, and finally to AI-powered virtual cells to maximize the experimental throughput of single-cell aging clocks.